Fecha de recepción: 17/05/2017 – Fecha de aceptación: 07/09/2017
Liñana Granell C, Ferrando Piqueres R, Álvarez Martín T, Mendoza Aguilera M, García Martínez T, Montañes Pauls B
Servicio de Farmacia Hospitalaria. Hospital General Universitario de Castellón (España)
Carla Liñana Granell
Hospital General Universitario Castellón
(Servicio de Farmacia)
Avda. Benicassim, s/n
12004 Castellón de la Plana
Correo electrónico: firstname.lastname@example.org
The objective of this study was to analyze pharmacological interactions between inhibitors of tyrosine kinase and the concomitant medication. The secondary objective was to evaluate the impact of the pharmaceutical intervention. A retrospective observational study was performed. To detect the interactions, a bibliographic search was made on the Up-to-date®, Lexicomp® and Micromedex® software platforms. A total of 28 patients were analyzed. 78.6% of patients had medication associated with the tyrosine kinase inhibitor. There were a total of 50 significant interactions, out of a total of 128 drugs, so the risk of having interaction in the study population was 39.1%. There were no significant differences in the number of interactions with respect to sex. Nor among patients who had less than 5 concomitant drugs and more than 5 drugs. Regarding the inhibitor of tyrosine kinase used, no significant differences were found either. Regarding the clinical significance of the interactions by the hematologist: 10 patients had 14 relevant interactions. Of these the doctor knew 50% and had performed intervention in all cases: modify the treatment in 28.6%, consulted with service responsible for treatment in 42.8% and spaced the intake of drugs in 28.6%. It was concluded that there exist an important risk of interactions with the tyrosine kinase inhibitor. In 12% of cases, the combination of drugs was contraindicated. The pharmaceutical interventions made in this regard were all accepted.
Key Words: Pharmacological interaction, tirosyne kinase inhibitor, chronic myeloid leukemia.